GHRP-6

GHRP-6 (Growth Hormone-Releasing Peptide-6) is a synthetic hexapeptide with the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2. It was developed in the early-to-mid 1980s by Cyril Y. Bowers and colleagues, arising from earlier structure-activity work on met-enkephalin analogues that unexpectedly displayed growth-hormone-releasing activity in pituitary cell culture unrelated to any opioid effect. Through iterative modification, Bowers’ group produced GHRP-6 as one of the first synthetic peptides shown to release growth hormone (GH) potently and dose-dependently, both in vitro and in vivo, via a receptor and mechanism distinct from that of growth hormone-releasing hormone (GHRH).

GHRP-6 belongs to the class of compounds now known as growth hormone secretagogues (GHS). Its pharmacological target, later named the growth hormone secretagogue receptor (GHS-R1a), was cloned in 1996, and in 1999 Kojima and colleagues identified the receptor’s endogenous ligand, a 28-amino-acid acylated peptide hormone secreted mainly by the stomach, which they named ghrelin. This places GHRP-6 in an unusual historical position: it is a synthetic ligand that was instrumental in the discovery of an entire endogenous signalling axis (the ghrelin/GHS-R1a system) years before that axis’s natural hormone was identified. Researchers remain interested in GHRP-6 both as a pharmacological tool for probing ghrelin receptor biology and, in earlier decades, as a candidate approach to stimulating endogenous GH secretion without administering exogenous recombinant GH.

1. Ghrelin Receptor (GHS-R1a) Agonism

GHRP-6 binds and activates GHS-R1a, a G-protein-coupled receptor expressed in the hypothalamus, pituitary, and other tissues, mimicking the action of endogenous ghrelin at this receptor. Activation of GHS-R1a in pituitary somatotrophs stimulates the phospholipase C pathway, generating inositol trisphosphate (IP3) and diacylglycerol, mobilizing intracellular calcium, and triggering GH release; this signal transduction cascade has been demonstrated directly in rat anterior pituitary cells.

2. Synergism with GHRH and Hypothalamic Somatostatin Suppression

GHRP-6’s GH-releasing action is functionally distinct from, and synergistic with, that of GHRH; co-administration of GHRP-6 and GHRH produces a greater GH response than either compound alone, suggesting the two act through separate, complementary pathways converging on the somatotroph. Part of GHRP-6’s action is also believed to occur at the hypothalamic level, where it is proposed to suppress somatostatin tone (a hormone that otherwise inhibits GH release) and/or stimulate hypothalamic GHRH release, in addition to its direct pituitary effects.

3. Central Appetite-Stimulating Activity

Because GHS-R1a is also the physiological ghrelin receptor and ghrelin is a well-characterized orexigenic (appetite-stimulating) hormone acting on hypothalamic feeding centers, GHRP-6’s activation of this same receptor produces pronounced appetite stimulation as a parallel, receptor-mediated effect distinct from its GH-releasing activity.

Cell Studies

In isolated rat anterior pituitary cell preparations, GHRP-6 has been shown to activate the inositol trisphosphate/diacylglycerol second-messenger pathway, directly linking receptor engagement to the intracellular signalling cascade responsible for GH secretion from somatotrophs.

Animal Studies

Early pharmacological characterization in several species demonstrated that GHRP-6 selectively and potently stimulates GH release in vivo, largely independent of GHRH but synergistic with it. Studies in neonatal rats found that GH release induced by GHRP-6 is not mediated via thyrotropin-releasing hormone, helping to isolate its mechanism from other hypothalamic-pituitary regulatory loops.

Human Clinical and Cosmetic Studies

GHRP-6 has been studied in human subjects via intravenous, subcutaneous, intranasal, and oral routes. In healthy adult volunteers, a single synthetic hexapeptide (GHRP-6) selectively stimulated GH release in a dose-related manner. In a study of children with normal short stature, oral administration of GHRP-6 to thirteen children (mean ages roughly 6 to 10 years) produced a GH response comparable in some respects to that seen with GHRH administration, supporting oral bioavailability of the GH-releasing effect in a pediatric population. Studies of intranasal administration have shown that substantially higher doses are needed by this route to achieve GH release comparable to intravenous dosing, reflecting lower bioavailability via nasal mucosa. Across these human studies, appetite stimulation has been a consistently observed accompanying effect, attributed to concurrent activation of the ghrelin receptor in central appetite-regulating circuits. No large, modern, placebo-controlled trials assessing long-term clinical outcomes (such as sustained changes in body composition or IGF-1 over months to years) in a general adult population have been published; the existing human literature is concentrated in short-duration, small-cohort pharmacodynamic studies from the late 1980s through the 1990s.

Short-term human studies report that GHRP-6 administration is generally well tolerated, with the most consistently reported effects being pronounced appetite stimulation and, at higher doses, mild and generally transient elevations in cortisol and prolactin secretion, reflecting the peptide’s action on hypothalamic-pituitary regulatory circuits beyond the GH axis. Repeated or continuous administration has been associated with desensitization of the GH-releasing response in some experimental paradigms, consistent with receptor downregulation upon sustained agonist exposure. Comprehensive, modern long-term toxicology and safety data in humans, including data on chronic administration, use in specific patient populations, or interactions with other medications, are not available in the published literature. GHRP-6 is not approved as a drug for any indication by regulatory authorities such as the FDA or EMA and is not intended for human or animal administration outside of a controlled laboratory research setting.

GHRP-6 occupies a distinctive place in endocrine pharmacology: a synthetic compound developed before its own receptor and endogenous ligand were known, whose study directly enabled the discovery of the ghrelin signalling system. Mechanistically, its GHS-R1a agonism and downstream IP3/DAG-mediated pituitary signalling are well characterized in cell and animal studies, and its GH-releasing and appetite-stimulating effects have also been demonstrated in small human pharmacodynamic studies spanning intravenous, subcutaneous, oral, and intranasal routes. However, the human evidence base is dated, limited to short-duration studies with small cohorts, and does not include the kind of large, controlled, long-term trials that would be needed to establish a modern clinical safety and efficacy profile. GHRP-6 has no regulatory approval for human or veterinary therapeutic use in any jurisdiction and is supplied strictly for laboratory research purposes.

GHRP-6. Wikipedia.

Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Communications.

Growth Hormone Releasing Hexapeptide, overview. ScienceDirect Topics.

1. Bowers CY, Momany FA, Reynolds GA, Hong A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 1984;114(5):1537-1545.

2. Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974-977.

3. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656-660. doi: 10.1038/45230.

4. Growth hormone releasing hexapeptide (GHRP-6) activates the inositol (1,4,5)-trisphosphate/diacylglycerol pathway in rat anterior pituitary cells. PMID: 8903947.

5. Bowers CY. Growth hormone-releasing peptide (GHRP). Cell Mol Life Sci. 1998;54(12):1316-1329.

6. Growth Hormone Release Induced by Growth Hormone-Releasing Hexapeptide Is Not Mediated by Thyrotropin-Releasing Hormone in Neonatal Rats. Pediatr Res. 1997.

7. Effect of a new synthetic hexapeptide to selectively stimulate growth hormone release in healthy human subjects. PMID: 2543692.

8. Bellone J, Ghizzoni L, Aimaretti G, et al. Growth hormone-releasing effect of oral growth hormone-releasing peptide 6 (GHRP-6) administration in children with short stature. Eur J Endocrinol. 1995;133(4):425-429. doi: 10.1530/eje.0.1330425.

9. Intranasal Delivery of a Ghrelin Mimetic Engages the Brain Ghrelin Signaling System in Mice. PMC11795113.